TYK2 - tyrosine kinase 2 Gene

Species: Macaca mulatta

Gene Type: protein coding
Gene ID: 574130

About TYK2

Primary_assembly 19: 10,110,172-10,145,150 reverse strand.Mmul_10:CM014354.1

This gene has 3 transcripts (splice variants), 197 orthologues and 32 paralogues.

TYK2 Products (7)

mRNA Protein Name
XM_028839940.1 XP_028695773.1 non-receptor tyrosine-protein kinase TYK2 isoform X1
XM_028839937.1 XP_028695770.1 non-receptor tyrosine-protein kinase TYK2 isoform X1
XM_028839939.1 XP_028695772.1 non-receptor tyrosine-protein kinase TYK2 isoform X1
XM_028839941.1 XP_028695774.1 non-receptor tyrosine-protein kinase TYK2 isoform X2
XM_028839938.1 XP_028695771.1 non-receptor tyrosine-protein kinase TYK2 isoform X1
XM_028839944.1 XP_028695777.1 non-receptor tyrosine-protein kinase TYK2 isoform X4
XM_028839942.1 XP_028695775.1 non-receptor tyrosine-protein kinase TYK2 isoform X3

TYK2 Protein Structure

FERM_F1

FERM_F1: pfam18379 (27 - 124)

FERM_F2

FERM_F2: pfam18377 (142 - 265)

Jak1_Phl

Jak1_Phl: pfam17887 (284 - 431)

SH2

SH2: cl15255 (436 - 533)

PTK_Tyk2_rpt1

PTK_Tyk2_rpt1: cd05076 (588 - 866)

PTKc_Tyk2_rpt2

PTKc_Tyk2_rpt2: cd05080 (894 - 1176)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1190 a.a.
Protein Preferred Names Protein Names

non-receptor tyrosine-protein kinase TYK2

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (19)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-50856 Ruxolitinib Inhibitor 99.99% Yes
HY-19569 Upadacitinib Inhibitor 99.98% Yes
HY-15315 Baricitinib Inhibitor 99.97% Yes
HY-117287 Deucravacitinib Inhibitor 99.93% Unkown
HY-50858 Ruxolitinib phosphate Inhibitor 99.97% Yes
HY-16379 Pacritinib Inhibitor 99.93% Yes
HY-107429 Abrocitinib Inhibitor 99.26% Unkown
HY-18300 Filgotinib Inhibitor 99.77% Yes
HY-19568 Peficitinib Inhibitor 99.43% Yes
HY-15315A Baricitinib phosphate Inhibitor 99.97% Yes
HY-109053 Delgocitinib Inhibitor 99.61% Unkown
HY-13577 Oclacitinib Inhibitor 99.03% Unkown
HY-13577A Oclacitinib monomaleate Inhibitor 99.87% Unkown
HY-18300A Filgotinib maleate Inhibitor 99.88% Yes
HY-50859 Ruxolitinib sulfate Inhibitor / Unkown
HY-19569A Upadacitinib tartrate tetrahydrate Inhibitor / Unkown
HY-19568A Peficitinib hydrobromide Inhibitor / Unkown
HY-16379A Pacritinib hydrochloride Inhibitor / Unkown
HY-19568B Peficitinib hydrochloride Inhibitor / Unkown

Clinical Phase

Bioactive Molecules (12)
Cat. No. Product Name Effect
Purity Phase
HY-15999 Cerdulatinib Inhibitor 99.06% Phase 3
HY-12469 Decernotinib Inhibitor 99.91% Phase 3
HY-112724 Ivarmacitinib Inhibitor 99.62% Phase 3
HY-174905 Quecitinib Inhibitor 99.56% Phase 3
HY-15999A Cerdulatinib hydrochloride Inhibitor 98.96% Phase 3
HY-13034 Gandotinib Inhibitor 99.86% Phase 2
HY-15270 BMS-911543 Inhibitor 98.23% Phase 2
HY-19631A Ilginatinib Inhibitor 99.81% Phase 2
HY-156961 Cadefrecitinib Inhibitor 99.81% Phase 2
HY-19631B Ilginatinib hydrochloride Inhibitor 98.92% Phase 2
HY-19631 Ilginatinib maleate Inhibitor 99.33% Phase 2
HY-101024 PF-06263276 Inhibitor ≥99.0% Phase 1

Pre-clinical Phase

Bioactive Molecules (60)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-14435 Pyridone 6 Inhibitor 98.20% Unkown
HY-14722 NVP-BSK805 Inhibitor 99.30% Unkown
HY-131968 BMS-986202 Inhibitor 99.29% Unkown
HY-100895 SAR-20347 Inhibitor 97.27% Unkown
HY-158142 PROTAC TYK2 degrader-1 Degrader 99.55% Unkown
HY-113787 (R)-9b Inhibitor 99.51% Unkown
HY-160144S Lomedeucitinib Inhibitor 99.75% Unkown
HY-153701S Envudeucitinibum Inhibitor 99.56% Unkown
HY-14722A NVP-BSK805 dihydrochloride Inhibitor 99.36% Unkown
HY-16640 TCJL37 Inhibitor 99.89% Unkown
HY-126242S Tyk2-IN-7 Inhibitor 99.58% Unkown
HY-101762 TyK2-IN-2 Inhibitor 99.05% Unkown
HY-111745 Tyk2-IN-5 Inhibitor 99.35% Unkown
HY-131906 JAK2-IN-7 Inhibitor 98.31% Unkown
HY-150720 TYK2-IN-12 Inhibitor 98.81% Unkown
HY-153440 Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate Inhibitor 98.01% Unkown
HY-120469 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide Inhibitor 99.80% Unkown
HY-111750 JAK-IN-3 Inhibitor 98.92% Unkown
HY-13961 GLPG0634 analog Inhibitor 98.07% Unkown
HY-126141 JAK/HDAC-IN-1 Inhibitor 98.63% Unkown
HY-152080 Blovacitinib Inhibitor 99.71% Unkown
HY-159536 Frevecitinib Inhibitor 99.42% Unkown
HY-143884 JAK2/TYK2-IN-1 Inhibitor 99.94% Unkown
HY-148060 JAK-IN-21 Inhibitor 99.72% Unkown
HY-18710 BMS-066 Inhibitor 99.09% Unkown
HY-170772 Dual Cathepsin L/JAK-IN-1 Inhibitor 98.47% Unkown
HY-18315 Bayer-18 Inhibitor / Unkown
HY-184075S Nomelcitinib Inhibitor / Unkown
HY-14722C NVP-BSK805 trihydrochloride Inhibitor / Unkown
HY-154994 JAK-IN-30 Inhibitor / Unkown
HY-177131 Soficitinib Inhibitor / Unkown
HY-153058 LRRK2-IN-8 Inhibitor / Unkown
HY-153103 LRRK2/NUAK1/TYK2-IN-1 Inhibitor / Unkown
HY-N14094 Tubulosine Inhibitor / Unkown
HY-177130S Socrodeucitinib Inhibitor / Unkown
HY-174430 WWQ-131 Inhibitor / Unkown
HY-168269 Tyk2-IN-20 Inhibitor / Unkown
HY-181278 Deucravacitinib analog 1 / Unkown
HY-401428 TYK2 ligand 3 Degrader / Unkown
HY-175684 JAK2-IN-14 Inhibitor / Unkown
HY-163304 Tyk2-IN-16 Inhibitor / Unkown
HY-175983 JAK1/TYK2-IN-5 Inhibitor / Unkown
HY-158340 TYK2 ligand 1 Inhibitor / Unkown
HY-158692 Tyk2-IN-18 Inhibitor / Unkown
HY-168339 Tyk2-IN-22 Inhibitor / Unkown
HY-18709 Tyk2-IN-3 Inhibitor / Unkown
HY-175310S Voderdeucitinib Inhibitor / Unkown
HY-147754 JAK3/BTK-IN-6 Inhibitor / Unkown
HY-178282 JAK1-IN-19 Inhibitor / Unkown
HY-149283 JAK/HDAC-IN-2 Inhibitor / Unkown
HY-149296 JAK1-IN-12 Inhibitor / Unkown
HY-143885 JAK1/TYK2-IN-3 Inhibitor / Unkown
HY-176793 JAK1-IN-18 Inhibitor / Unkown
HY-112783 TYK2 ligand 4 Ligand / Unkown
HY-173359 TYK2 ligand 2 Ligand / Unkown
HY-162862 JAK-IN-38 Inducer / Unkown
HY-157121 JAK-IN-34 Inhibitor / Unkown
HY-123939 JAK1/3-IN-1 Inhibitor / Unkown
HY-162862 JAK-IN-38 Inhibitor / Unkown
HY-123187 AS2553627 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens TYK2 NCBI NCBI:7297